Harnessing aging to transform health
Obesity and other metabolic diseases are among the most prevalent and pressing health challenges of our time.
Age is a critical risk factor.
We are harnessing the biology of human aging to develop new therapies for metabolic diseases
We are harnessing the biology of human aging to develop new therapies for metabolic diseases
We are harnessing the biology of human aging to develop new therapies for metabolic diseases
Find out more
NLRP3:
anti-inflammatory for obesity
BGE-102, our lead program, has the potential to block the chronic inflammation linked to appetite dysregulation, insulin resistance, and cardiovascular risk.
We anticipate Phase 1 SAD data by 2025 year end.
APJ: exercise mimetic for obesity
Apelin is a molecule that is secreted in response to exercise. Agonism of the apelin receptor APJ has the potential to double weight loss and fully restore body composition on an incretin background in preclinical models of obesity.
Discovery platform
Our human-first discovery platform analyzes proprietary multi-omics data captured over decades to identify the molecular mediators of aging and disease.
Our pipeline programs target key pathways that drive metabolic aging based on novel insights from our platform.
Recent Press Releases
March 20, 2025
